Project Grant R01CA291991
Award Date
4/4/25
Completion Date
3/31/30
Dollars Obligated
$396K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $433,256 to the H. Lee Moffitt Cancer Center and Research Institute to conduct research on targeting a metabolic vulnerability in melanoma. The key objectives are to use genetic and pharmacological approaches to evaluate how reducing the expression of the enzyme PHGDH, combined with dietary serine restriction, can impact melanoma tumor growth in preclinical models. The research aims...
This $369,108 Project Grant awarded by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) funds research by The Broad Institute, Inc. to investigate the therapeutic potential of intentionally inducing resistance to BRAF and MEK inhibitors in melanoma. The goal is to demonstrate that melanoma cancers which develop resistance to these targeted therapies will become more susceptible to lethal MAPK pathway hyperactivation. The research will employ cellular...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research Program (CFDA 93.395), provides $198,103 to New York University School of Medicine to conduct research on understanding and addressing melanoma bone metastasis. The research aims to define the mechanisms by which melanoma cells colonize the skeletal microenvironment and modify the immune response, with a focus on the role of bone metastasis-associated neutrophils. Through preclinical...
This is a Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) to The Wistar Institute of Anatomy and Biology, totaling $614,911 and spanning from July 2024 to June 2029. The research project aims to define the molecular mechanisms underlying transcriptional reprogramming of melanoma cell plasticity and its impact on tumor progression and immune evasion. Key objectives include elucidating how the transcription factor TFEB regulates melanoma...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $423,468 to Harvard T.H. Chan School of Public Health to conduct research aimed at preventing melanoma metastasis by targeting lipid vulnerabilities in lymph nodes. The central objective is to identify and exploit lipidomic changes in melanoma cells within the lymphatic microenvironment that enable metastasis, with the goal of developing new interventions to prevent the spread...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $635,946 to support a research project led by Dartmouth-Hitchcock Clinic titled "Melanocyte PDL1 Control of UVB-Induced IFN-I". The project aims to investigate how ultraviolet B (UVB) radiation exposure affects immune responses and treatment resistance in melanoma tumors, with a focus on the role of melanocyte PD-L1 expression in modulating interferon-I...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $196,029 to the University of Massachusetts Medical School (UMass Medical) to support research aimed at deciphering the immune evasion mechanisms in cancers harboring mutations in the isocitrate dehydrogenase 1 (mIDH1) gene. The funded work will focus on two key objectives: 1) Elucidating the role of viral mimicry in the response to mIDH1 inhibition, and 2) Exploring the contribution...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,947,107 to the University of Florida to develop a novel proteolysis-targeting chimera (PROTAC) compound that degrades the nuclear receptor NR4A1 for melanoma therapy. The project aims to rationally design NR4A1-targeting PROTACs, determine their cellular and molecular mechanisms of action, and explore their therapeutic potential as a single agent or in combination with...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Johns Hopkins University provides $852,164 to investigate the impact of the plantar skin microenvironment on acral melanoma, a form of skin cancer that disproportionately affects the extremities. The 5-year study aims to mechanistically define how matrix stiffness in the plantar skin affects acral melanoma cell metabolism, metastasis, and therapy resistance. Specifically, the...
This $442,236.00 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will fund research at the University of Alabama at Birmingham (UAB) to investigate the role of the YTHDF1 RNA-binding protein in promoting melanoma metastasis. The key objectives are to determine how YTHDF1 drives melanoma cell anoikis resistance and suppresses anti-tumor immunity mediated by natural killer cells.
The research will utilize a range of in vitro and in...